ArticleOncology letters2018

Molecular screening and the clinical impacts of BCR-ABL KD mutations in patients with imatinib-resistant chronic myeloid leukemia.

Betül Koçkan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.